Abivax appoints Ana Sharma as VP, global head of quality

7 February 2024

French clinical-stage biotech Abivax (Euronext Paris: ABVX) today announced the appointment of Ana Sharma as vice president, global head of quality.

Ms Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance, Abivax noted. She has helped bring over 30 drugs to market across multiple therapeutic areas, including gastroenterology and immunology. She has experience managing large international teams and regulatory authority interactions and inspections worldwide.

Ana Sharma joined Abivax from Takeda (TYO: 4502), where she held the position of VP, global head of R&D clinical quality assurance. Previously, she worked for Novartis (NOVN: VX), Amgen (Nasdaq: AMGN) and Dana-Farber/Harvard Cancer Center where she occupied different quality positions with increasing levels of responsibility.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK